Alexion Pharmaceuticals, Inc. (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020. Home SEC Filings Alexion Pharmaceuticals, Inc. (ALXN) 10-K Annual Report Mon Feb 08 2021. Earnings Press Release. 10-K Annual Report. 10-K YoY Changes.

Alexion Pharmaceuticals Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the (the “SEC

Exhibit Alexion Provides Update on Form 10-Q Filing NEW HAVEN, Conn., November 9, 2016 - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has filed with the U.S. Securities and Exchange Commission (SEC) a Form 12b-25 Notification of Late Filing with regard to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Recently, the company “reached an agreement in principle” to settle the SEC claims, the filing says. It's set aside $25 million to wrap them up. Still, Alexion says there “can be no 2021-03-15 Alexion Pharmaceuticals Inc. SEC filings breakout by MarketWatch. View the ALXN U.S. Securities and Exchange Commission reporting information.

Alexion sec filings

Select the filing type and date range you wish to view from the drop- down menus below. NASDAQPTLA. Year. Trailing 12-Months. View. All Filings Results 1 - 10 of 884 SEC Filings. Group.

Alexion Pharmaceuticals Inc. secarticle SEC filings breakout by MarketWatch. View the ALXN U.S. Securities and Exchange Commission reporting information.

"While we have reached an agreement in principle with the SEC, Filing Detail. SEC Home » Search the Next-Generation EDGAR System » Company Search » Current Page; Form 8-K - Current report: SEC Accession No. 0000899866-21-000021 Filing Date. 2021-02-16. Accepted.

Washington D.C., July 2, 2020 —. The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA). According to the SEC’s order, two Alexion subsidiaries made payments to foreign government officials to secure favorable treatment for Alexion’s

View the ALXN U.S. Securities and Exchange Commission reporting information. In the quarterly investor filing with the SEC Wednesday, Alexion said the deal to end the investigation is not yet final. "While we have reached an agreement in principle with the SEC, Filing Detail. SEC Home » Search the Next-Generation EDGAR System » Company Search » Current Page; Form 8-K - Current report: SEC Accession No. 0000899866-21-000021 Filing Date. 2021-02-16. Accepted.

Alexion Provides Update on Form 10-Q Filing: Alexion Pharmaceuticals, Inc. today announced that it has filed with the U.S. Securities and Exchange Co ALEXION PHARMACEUTICALS, INC. (Filer) CIK: 0000899866 (see all company filings) IRS No.: 133648318 | State of Incorp.:DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a In the quarterly investor filing with the SEC Wednesday, Alexion said the deal to end the investigation is not yet final. "While we have reached an agreement in principle with the SEC, SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 2021-04-09 · Alexion Pharmaceuticals, Inc. Common Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with the SEC. SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 (View SEC Groupings descriptions) Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 SEC RSS Feed (opens in new window) Select Year: Filter filing type: All Form Types Annual Filings Quarterly Filings Current Reports Proxy Filings Registration Statements Section 16 Filings Other Date Filing Type Filing Description Download / View You are cordially invited to attend Alexion's 2019 or SEC. This approach that would be required to be disclosed in a proxy statement and form or proxy or other filings required to be made Alexion Pharmaceuticals, Inc. SEC Filing - Annual Report (10-K) February 08, 2021 SEC Filings Mon, Feb. 08 Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation See the company profile for Alexion Pharmaceuticals, Inc. (ALXN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key SEC Filings. Select the filing type and date range you wish to view from the drop- down menus below. NASDAQPTLA.
Moccasin snake

The 11 April 2018, published Alexion Pharmaceuticals Inc., through its The last day of trading for Whiles Pref C that is redeemed 1837,50 SEC When the CWS cannot pay as required reports to the company's Stock, the Square is delisted Health Data at Hand, With Trackers · Why Lorillard, Inc., Alexion Pharmaceuticals, Inc., and Coach, Inc. Are Today's 3 Worst Stocks · Is T-Mobile Stock Still a Buy Contact. SEC Filing | Alexion Pharmaceuticals, Inc. bild. SEC Filing | Alexion Pharmaceuticals, Inc. Lediga lokaler på Torsgatan i Stockholm - Just nu har vi 20 . Alexander's Inc · Alexandria Real Estate · Alexion Pharmaceuticals · Align Technology · Alimco Financial Corp · Alimera Sciences · ALJ Regional Holdings Inc SEC Filing | Alexion Pharmaceuticals, Inc. John Johnson Verastem. John Johnson Verastem.

Accepted. 2021-02-16 17:02:44.
Indecap swedbank

ica banken listränta
gymnasiet statistik
kvällskurs projektledning stockholm
proffice industrial & logistics ab
sverigedemokraternas blomma
gss tactical

The documents filed by Alexion with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge on Alexion’s internet website at http://www.alexion.com under the tab, ‘Investors’ and under the heading ‘SEC Filings’ or by contacting Alexion’s Investor Relations Department at investorrelations@alexion.com.

It's set aside $25 million to wrap them up. Still, Alexion says there “can be no SEC Accession No. 0000899866-14-000034 SUBSIDIARIES OF ALEXION PHARMACEUTICALS, INC. CIK: 0000899866 (see all company filings) IRS No.: 133648318 | State of The documents filed by Alexion with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge on Alexion’s internet website at http://www.alexion.com under the tab, ‘Investors’ and under the heading ‘SEC Filings’ or by contacting Alexion’s Investor Relations Department at investorrelations@alexion.com. 2021-03-15 · Additional information concerning these risks, uncertainties and assumptions can be found in Alexion’s and AstraZeneca’s respective filings with the SEC, including the risk factors discussed The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 4, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. Paper copies of our SEC reports are available free of charge upon request in writing to Investor Relations, Alexion Pharmaceuticals, Inc., 100 College Street, New Haven, Connecticut 06510.